Status:
TERMINATED
An Explorative Study of Treatment of Contact Dermatitis Due to DiabetesDevices
Lead Sponsor:
Copenhagen University Hospital at Herlev
Conditions:
Contact Dermatitis Irritant
Type 1 Diabetes
Eligibility:
All Genders
6-20 years
Phase:
NA
Brief Summary
A feasibility study of treatment with a occlusive medical device or patch in pediatric patients with type 1 diabetes suffering from irritative contact dermatitis due to diabetes devices.
Eligibility Criteria
Inclusion
- Signed informed consent, and for patients under the legal age consent by a legal guardian
- Clinically confirmed, active and evaluable irritant contact dermatitis (ICD)
- Age 6-20 at the time of signing the informed consent form (ICF)
- Ability to answer study questionnaires
Exclusion
- Any type of skin irritation other than ICD
- Use of occlusive therapy for the treatment of their ICD, or unwilling to refrain from this treatment for duration of study
- For any other reason considered unsuitable by the investigator
- Pregnant or of child-bearing potential unwilling to use acceptable effective contraception
Key Trial Info
Start Date :
May 19 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2022
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT04909983
Start Date
May 19 2021
End Date
October 1 2022
Last Update
November 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pediatric Department, Herlev Hospital
Herlev, Denmark, 2730